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a  b  s  t  r  a  c  t
Recent  ﬁndings  provide  evidence  for a functional  interplay  between  DNA  replication  and  the  seemingly
distinct  areas  of cancer,  development  and  pluripotency.  Protein  complexes  participating  in  DNA  replica-
tion  origin  licensing  are  now  known  to have  roles  in development,  while  their  deregulation  can  lead  toeywords:
NA replication
icensing
rigin speciﬁcation
ancer
luripotency
cancer.  Moreover,  transcription  factors  implicated  in  the maintenance  of  or reversal  to  the  pluripotent
state  have  links  to the  pre-replicative  machinery.  Several  studies  have shown  that  overexpression  of
these factors  is  associated  to cancer.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).evelopment
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. Introduction
DNA replication is initiated from a large number of origins
of DNA replication at an origin is a highly regulated process that
commences with origin licensing, during which a multiprotein
complex, named the pre-replicative complex is formed at originshat are activated in each cell cycle (∼50,000 in human or mouse
ells). Throughout the genome there are many more potential
rigins that are not in use by the cell at a speciﬁc time. Initiation
∗ Corresponding author.
E-mail addresses: schamperis@upatras.gr (S. Champeris Tsaniras),
anellakis@upatras.gr (N. Kanellakis), eleannasym@googlemail.com
I.E. Symeonidou), pinelopinik@hotmail.com (P. Nikolopoulou),
ygerou@med.upatras.gr (Z. Lygerou), taraviras@med.upatras.gr (S. Taraviras).
ttp://dx.doi.org/10.1016/j.semcdb.2014.03.013
084-9521/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unof DNA replication. Thereafter, a subset of these origins will be
activated and DNA replication will be initiated from these origins
during S phase (see review by Speck et al. in this issue).
In the present review we will focus on the proteins participating
in the assembly of the pre-replicative complex (pre-RC) at origins
of DNA replication, an essential step for replication initiation.
This complex is assembled dynamically onto chromatin and
consists of the origin recognition complex (ORC), Cdc6, Cdt1 and
MCM proteins. Subsequent origin ﬁring results in the inactivation
of the pre-RC, while its subunits are negatively regulated by
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Interactions of the pre-replicative complex members (Cdc6, ORC, Mcm2-7
and  Cdt1), and the Cdt1 inhibitor, Geminin, with transcription factors and proteins
participating in chromatin remodeling. Bmi1 interacts with Cdc6; Hbo1 with Cdt1,
Orc1 and Mcm2;  c-myc with MCM2-MCM7, ORC2, Cdt1 and Cdc6 whereas Klf4 has
been reported to induce transcription of Mcm2.  Antagonism between Geminin and
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wrg1 has been proposed to maintain expression of Oct4, Sox2 and Nanog. Geminin
lso  interacts with Hox proteins and inhibits the interaction between HoxD13 and
dc6.
ifferent mechanisms [1–4]. One of the major components of the
re-replicative complex is the Cdt1 protein which is responsible
or loading the MCM  proteins onto origins of replication. It is
egatively regulated by ubiquitin-dependant proteolysis and a
mall protein inhibitor present in metazoa, named Geminin [4,5],
orging very tight control over the process.
However, increasing lines of evidence suggest that DNA repli-
ation mechanisms have a much higher level of complexity than
reviously thought (Fig. 1). Flanagan and Peterson [6] showed that
ertain yeast replication origins depend on the SWI/SNF complex
or their proper function while CDC6 was recently shown to inter-
ct with Bmi1, a member of the Polycomb group of proteins, in
ouse embryonic ﬁbroblasts (MEFs) [7]. More importantly, mem-
ers of the Hox family of transcription factors, known for their
ole in development, were shown to directly interact with yeast
nd human replicative complexes. Human HoxA13, HoxC10 and
oxC13 were ﬁrst identiﬁed in a yeast one-hybrid screen [8].
oxC10 and HoxC13 were subsequently shown to interact with
uman origins [9], while altering the chromatin structure dimin-
shes the interactions between the origins and HoxC13 [10].
Yet, in contrast to yeast, no consensus nucleotide sequence has
een identiﬁed in any replication origin of metazoa. The DNA of the
atter contains many possible origins but only few are activated
uring each genome duplication, a concept known as the Jesuit
odel of replication [11]. It thus seems possible that the activation
f metazoan origins is part of a complex system, incorporating epi-
enetic and transcriptional controls. In this regard, this review will
ocus on the interconnections between DNA replication, develop-
ent and pluripotency and how perturbations within these “states”
an lead to genomic instability and cancer.
. DNA replication licensing and development
.1. DNA replication origin speciﬁcation and developmentDuring development, extensive physiological changes are
bserved, as stem and progenitor cells initiate fate speciﬁcation
rograms and undergo terminal differentiation, while a population
ith self-renewing properties is maintained. It has been speculatedevelopmental Biology 30 (2014) 174–180 175
that these processes are interlinked with changes in transcriptional
programs and chromatin reorganization and can inﬂuence origin
selection, while a reciprocal regulation is also possible.
MacAlpine et al. [12] were the ﬁrst to use a systematic microar-
ray approach in Drosophila to unravel a temporal replication pattern
correlating to active transcription density. Sequeira-Mendes et al.
[13] then employed mouse embryonic stem cells to identify a
remarkable 85% of replication origins that were correlated to trans-
criptional units. In line with this, it was recently shown that
genomic sites of ORC1, one of the main proteins regulating ori-
gin selection, were correlated to transcription start sites of coding
and non-coding RNAs, while its transcription levels were associated
with replication timing [14]. Moreover, it has been suggested that
DNA replication origins are organized in a high order structure [15].
Understanding how replication origin clustering and speciﬁcation
takes place during development will shed light in the interplay
between origin selection, transcriptional and chromatin organiza-
tion.
An open chromatin structure is preferred for the localization
of active origins of replication, while several histone modiﬁca-
tions have been linked with pre-RC member accumulation, origin
speciﬁcation and ﬁring (for a review see [16,17]). Origin presence
correlates with open chromatin conformation, linked with H3K4
methylation [18] while acetylation of the H3 and H4 histones is
necessary for the efﬁcient ﬁring of origins [19]. Rizzardi et al. [20]
subsequently showed that the loss of H3K4 di-methylation in yeast
causes replication defects, suggesting that this type of modiﬁcation
is required for proper origin function. In line with this, dimethyla-
tion of histone H3 lysine K79 (H3K27Me2) was  shown to occur in
a signiﬁcant fraction of human origins, with evidence suggesting
that it could be associated to the order and timing of their ﬁring
[21]. In addition, increased levels of nucleosome acetylation have
been identiﬁed in active origins during Drosophila development,
revealing a quantitative relationship between the former and origin
ﬁring activity. In contrast, acetylation levels were found to decrease
when transcription is initiated and neighboring origins are inactiv-
ated [22]. The histone acetyltransferase, Hbo1, has been shown to
interact with Orc1 and Cdt1 linking acetylation with opening of the
chromatin and origin licensing [23,24]. Methylation of histone H4
at the lysine K20 has also been implicated in the pre-RC assembly
at origins of replication [25–27].
There are also several studies highlighting the interplay
between origin speciﬁcation and transcriptional regulation. Cdc6,
a member of the pre-RC complex, is able to repress CDH1 tran-
scription through binding to its promoter. This results in the
displacement of CTCF, a transcriptional repressor that acts as a
chromosomal insulator, and activation of alternative origins of
replication [28]. Similarly, binding of certain transcription factors,
including c-Myc and GATA1, has been shown to be associated with
DNA replication origin activity [29,30]. Changes in the origin usage
have also been reported within the HoxB locus during differen-
tiation of mouse embryonic carcinoma cells, suggesting that this
process might have a role to play in regulating the developmental
expression of HoxB genes [31].
2.2. Developmental roles of pre RC components
Pre-replicative complex components have been suggested to
play distinct roles in several developmental processes, with Gem-
inin having one of the most prominent. Besides its role in cell
cycle regulation [5], Geminin was  initially characterized by its
ability to expand neural plate in Xenopus embryos, when overex-
pressed [32]. During corticogenesis, Geminin is important for the
regulation of self-renewal and differentiation decisions of neural
progenitor cells [33], while T cell development in thymus remains
unaffected by the absence of Geminin [34,35]. Furthermore, during
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hick development, it participates in axial patterning establishment
hrough Polycomb mediated regulation of Hox gene expression
36]. Similarly, direct interaction with the homeobox containing
ranscription factor Six3 controls cellular proliferation and differ-
ntiation during eye development in Medaka embryogenesis [37].
n addition, antagonistic interactions between Geminin and mem-
ers of the b-HLH family of transcription factors for the binding of
rg1, the catalytic subunit of the SWI/SNF chromatin remodeling
omplex, have been proposed to regulate the transition from a neu-
al progenitor cell to a differentiated cell in P19EC cells and Xenopus
mbryos [38–41]. Antagonism between Geminin and Brg1 has also
een proposed to control acquisition of trophoectoderm markers
nd maintain expression of the core pluripotency genes in mouse
mbryonic stem (ES) cells [42]. In a recent study by Kroll’s group,
t was suggested that Geminin antagonizes bHLH transcription fac-
ors that promote neurogenesis by maintaining the bivalent status
f their promoters [43].
During the early steps of Xenopus embryogenesis,  Lim et al. [44]
howed that Geminin restricts mesoderm, endoderm and ectoderm
ommitment by promoting Polycomb and Polycomb-mediated
epressive modiﬁcations. However, neural fate acquisition of ES
ells has been shown to be dependent on Geminin expression which
aintains hyperacetylation and expression of neural genes [45].
he mechanistic model by which Geminin exercises this role is not
nderstood and results from different studies are often contradict-
ng, suggesting that more experiments are necessary to establish
he role of Geminin and possibly integrate its role in development
nd licensing regulation.
The partner of Geminin, Cdt1, is expressed in cortical pro-
enitors during embryogenesis; however, there are currently no
vailable data on its role [46]. Two different Cdc6 isoforms have
een shown to be differentially regulated during Xenopus embryo-
enesis, linking changes in the cell cycle pattern to development
47]. MCM  gene expression is an excellent marker for detecting
roliferation as well as stem cells during embryogenesis [48].
epletion of MCM5  in zebraﬁsh and speciﬁc mutations leads to
evelopmental defects in certain proliferating tissues [49], while
 hypomorphic allele in mice is linked to defects with stem cell
opulations [50].
In addition, certain ORC core subunits have also been found
o regulate the development of dendrites and dendritic spines
n postmitotic neurons [51] while ORC3 was recently shown to
nduce neuronal maturation in cultured cerebellar granule cells by
nhibiting Rho [52]. Similarly, homozygous Drosophila mutants for
atheo, an ORC homologue, do not develop imaginal discs, have very
imited CNS development and die at the early pupae stage [53].
oth of these studies propose morphogenetic roles for ORC com-
onents, their function in the cell cycle aside. This is an intriguing
cenario and more studies are required to identify whether this is
lso the case for other proteins participating in the pre RC com-
lex.
Interestingly, mutations in the ORC1, ORC4, ORC6, CDT1 and
DC6 genes were recently linked to Meier–Gorlin syndrome (MGS),
 rare autosomal recessive disorder characterized by primordial
warﬁsm, microtia and patellar aplasia/hypoplasia [54,55]. ORC1
as also reported to contain a domain that interacts with histone
4 dimethylated at lysine 20 (H4K20me2). Deletion of this domain
as found to impair ORC1 function [25] while mutations have been
eported to play a role in the pathogenesis of MGS  [54,55]. These
tudies show that members of origin licensing are essential for DNA
eplication and therefore mutations are expected to lead to devel-
pmental defects leading to impaired cell proliferation and could
onsequently globally reduce growth.
Licensing of origins of DNA replication is an essential process
or DNA replication during development, however more research
s needed in order to clarify whether impaired cell proliferationevelopmental Biology 30 (2014) 174–180
and reduced growth might be the result of participation of the pre-
replicative complex components in other cellular functions besides
DNA replication [56,57].
3. Pre-RC member links with pluripotency
In ways that are not yet well understood, the origins of replica-
tion dynamics as well as the replication patterns seem to be linked
to the maintenance of pluripotency. The ﬁrst genome-wide study
to delve into this complex issue was  performed by Hiratani et al.
[58], who  identiﬁed certain chromosome parts in mouse ES cells
that replicated early in S phase, while others replicated late. Upon
loss of pluripotency and differentiation, this temporal pattern of
replication was altered, suggesting that the proﬁle of replication
domains is cell-type speciﬁc. The authors later identiﬁed such tem-
poral proﬁle changes in cell culture models of early to late epiblast
stage, coinciding with chromatin changes, before the germ layer is
speciﬁed and the core pluripotency factors Oct4, Nanog and Sox2
are downregulated [59]. They also demonstrated that such tempo-
ral replication programs are highly conserved in similar cell types
of different species [60]. Similarly, Schultz [61] analyzed human
ES and microvascular endothelial cells using a technique of single
molecule analysis of replicating DNA. He demonstrated that, within
a DNA segment containing the Oct4 gene, the origins of replication
are signiﬁcantly different between the two  cell types, highlight-
ing the changes the replication program undergoes upon loss of
pluripotency. In line with these, a recent study on ES cells and repro-
grammed ﬁbroblasts reported that certain replication domains can
become late replicating after the loss of certain esBAF components
like Brg1, while different members of the esBAF complex can mod-
ify the replication timing in distinct replication domains [62]. Of
note, esBAF is a chromatin remodeling complex that directly inter-
acts with pluripotency factors and is essential for the maintenance
of pluripotency [63].
Interestingly, DNA replication is required to activate pluripo-
tency genes [64], while the cell cycle is important for the
reprogramming of somatic cells [65]. Similarly, it was recently
reported that DNA replication is an early and critical event in the
epigenetic reprogramming of somatic cells in experimental ESC-
heterokaryons [66].
In addition, a signiﬁcant number of manuscripts provide evi-
dence for the pre-RC inhibitor Geminin and its role in regulating
pluripotency, stem cell self-renewal and differentiation [42,44,67].
Mouse embryos that lack Geminin expression fail to develop
beyond the 8-cell stage and do not form an inner cell mass
[68,69]. Thereafter, Geminin expression is necessary for maintain-
ing expression of the core pluripotency genes, i.e. Oct4, Sox2 and
Nanog, in mouse ES cells, by antagonizing the SWI/SNF protein
Brg1 [42]. In line with this, it was  recently found that SRR2, a
Sox2 enhancer, is epigenetically activated in the presence of Gemi-
nin, but repressed otherwise [67]. The latter study reported that
Geminin downregulation causes mouse ES cells to differentiate
toward mesendoderm, characterized by high Oct4/low Sox2 lev-
els; however, Yang et al. [42] reported that Geminin deﬁciency
results in differentiation toward an extraembryonic route. In addi-
tion, another study investigating Geminin overexpression in mouse
ES cells reported differentiation toward the neural lineage when
cultured as a monolayer but differentiation toward mesendoderm
in a three-dimensional culture [70].
Perhaps the most overlooked aspect linking pluripotency to DNA
replication are the interactions of the main pluripotency-associated
transcription factors with the latter. Using gene expression proﬁl-
ing and gene ontology (GO) analysis, Campbell et al. [71] reported
that Oct4 in ES cells is associated with GO categories represent-
ing transcription and DNA replication, among others. Similarly, the
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verexpression of Nanog, the other core ES cell pluripotency fac-
or, was found to upregulate genes related to cell cycle control and
NA replication in mesenchymal stem cells, while also dediffer-
ntiating them [72]. Along these lines, when analyzing the Sox2
nteractome in ES cells, Gao et al. [73] found that this factor is asso-
iated with the DNA replication machinery proteins Polb, Rpa1,
pa2 and Rpa3. Furthermore, even more surprisingly, stronger links
xist between pluripotency and the transcription factors Klf4 and
-myc, whose forced expression, together with Sox2 and Oct4, are
nown to generate induced pluripotent stem cells, i.e. reprogram
ifferentiated somatic cells back to pluripotency [74]. In the uterine
pithelium, Klf-4 was reported to bind to the promoter of MCM2
nd induce its transcription [75], while Klf circuitry of transcription
actors is important for regulating self-renewal of embryonic stem
ells, which includes members of the MCM  family [76]. In addition,
-Myc has been reported to promote DNA replication via a non-
ranscriptional mechanism, leading to premature origin ﬁring and
ncreases in origin density. This factor was shown to directly bind
o the pre-RC complex and co-puriﬁed with MCM2-MCM7, ORC2,
dt1 and Cdc6. Its ablation inhibited DNA replication, at least in part
ue to non-transcriptional effects, while its overexpression caused
ncreased activity of replication origins [77,78].
. DNA replication licensing, pluripotency and cancer
.1. Pre-RC components and oncogenesis
It is essential for the genetic material to be fully and correctly
eplicated within one cell cycle, in order for genetic information to
e transmitted into the daughter cells. It is established that licens-
ng of DNA replication origins mediated by pre-RC components is
n essential mechanism for the maintenance of genomic integrity,
s over-licensing and under-licensing contribute to aberrant DNA
eplication [79].
The expression of pre-RC proteins is increased in cancer, as
 result of increased cell division and DNA replication. However,
part from their role as proliferation markers, there is strong evi-
ence that several of these proteins have oncogenic properties per
e, and their dysregulation can induce genomic instability [80].
bberant regulation of Cdt1 has been suggested to promote re-
ring of the same origins which promotes genomic instability and
redisposes cells for malignant transformation (reviewed by [81]).
ore speciﬁcally, Cdc6 has also been shown to be linked with re-
eplication, together with Cdt1, in different tumorigenic cell lines
nd human specimens [82–86]. Cdt1 and Cdc6 expression was  stud-
ed in non-small cell lung carcinomas and their overexpression
as suggested to act cooperatively with p53 mutation, promot-
ng tumor growth, genomic instability and correlates with adverse
rognosis for these patients [87]. Furthermore, in a subsequent
tudy it was shown that deregulated expression of Cdc6 and Cdt1
s observed at the early stages of hyperplasia and dysplastic epithe-
ium [84]. Cdc6 and Cdt1 overexpression in tumorigenic cell lines
romoted re-replication and generated a DNA damage response,
hich activated mechanisms promoting senescence and apoptosis
84]. The cells that combine Cdt1 and Cdc6 overexpression with
efects in the p53 pathway revealed more aggressive properties
nd exhibited features of epithelial to mesenchymal transition, sug-
esting that overexpression of these factors might contribute to
ancer invasion and metastasis [28,84]. Further in vivo evidence
f the ability of Cdt1 to promote tumorigenesis were provided by
verexpression of Cdt1 in T cells that led to the development of
ymphoblastic lymphomas in the absence of p53 [88].
An alternative model on how pre-RC members can contribute
o tumorigenesis was suggested by Gonzalez et al. as Cdc6 over-
xpression lead to transcriptional repression of INK4/ARF locus,evelopmental Biology 30 (2014) 174–180 177
which is one of the most frequent events in human cancer [89].
The mechanism of Cdc6 mediated transcriptional silencing involves
chromatin heterochromatinisation, through recruitment of histone
de-acetylases, while cooperation with other oncogenic signaling
mechanisms promotes neoplastic transformation [89].
In addition, the expression of CDC6 and MCM5  has been
reported to correlate with the grade of dysplasia in cervical prema-
lignancy and cancer [90]. In line with this, dysregulation of different
MCM  proteins has been demonstrated in several premalignancies
and cancers, including breast, renal, skin and oesophageal [91–93].
Moreover, a mutation of MCM4  termed Chaos3 (chromosome aber-
rations occurring spontaneously 3) is a viable allele and causes
adenocarcinoma [94–96]. Mice with reduced expression of MCM2
develop normally but their life span is greatly reduced because of
lymphomas [50].
Cancer studies implicating the ORC subunits are lacking; how-
ever, deletion of the ORC5L subunit has been identiﬁed in a
signiﬁcant number of acute myeloid leukemias [97]. Interestingly,
HoxC13 as well as Topoisomerase I and II, which are not pre-RC
components but part of the replicative complex, cause myeloid
leukemia when fused to the nucleoporin 98 gene [98–100], pos-
sibly due to their deregulated transcription, as a result of the fusion
[101].
Ablation of Cdt1’s inhibitor, Geminin, leads to re-replication
[102,103]. Studies on human cell lines and Xenopus have reported
that Geminin ablation results in genome over-replication and DNA
damage [102,104]. In addition, Geminin downregulation has also
been shown to cause centrosome overduplication and abnormal
chromosome segregation [105]. On the other hand, the situation
appears to be more complex in vivo; as conditional knockout mice
lacking Geminin in the lymphoid compartment and central nervous
system are viable with no signs of cancer development ([33,34];
Taraviras S, unpublished observations). Moreover, high Geminin
expression was found to be associated with the expression of
CD133, a well-known cancer stem cell marker, in a subset of breast
carcinomas [106], possibly effecting cancer stem cell characteristics
in tumor cells.
4.2. Pluripotency-associated factors and cancer
The role of pluripotency-associated factors in pathological self-
renewal states and cancer is becoming increasingly clear, due to
several recent landmark studies. In this regard, Chen et al. [107]
showed that Oct4 is essential for maintaining the self-renewing
properties of cancer stem cell (CSC)-like cells isolated from patients
with non-small cell lung carcinoma. More surprisingly, Kumar et al.
[108] showed that forced Oct4 expression in melanoma cells caused
their dedifferentiation to CSC-like cells while, very recently, it was
demonstrated that Oct4 promotes carcinogenesis and inhibits apo-
ptosis in cervical cancer [109]. Similarly, Sox2 has been shown to
induce dedifferentiation in human pancreatic cancer cells while
enhancing their cellular proliferation [110] and it has also been
suggested to promote carcinogenesis of lung cancer by attribut-
ing CSC-like properties to the cells [111]. Correspondingly, Nanog
has been reported to induce CSC-like phenotypes in colon can-
cer [112,113] as well as the development and metastasis of breast
cancer [114].
Along these lines, the c-myc, Klf4, Lin28 and Bmi1 transcription
factors, relevant to induced pluripotent stem cell generation,
also play similar roles. c-Myc is deregulated in several human
malignancies including breast, colon and prostate cancer [115],
while its overexpression has been reported to increase the activity
of replication origins and induce DNA damage [77]. Similarly, Klf4
confers CSC-like properties in colon cancer cells [116], has been
shown to induce a CSC population in vitro and has been suggested
to play a central role in the development and metastasis of breast
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lig. 2. A holistic model depicting the possible interconnections between the pre-RC
omponents, pluripotency factors, epigenetic modiﬁcations and the pattern of DNA
eplication origin ﬁring.
ancer [117]. Lastly, Bmi1 is necessary for tumor growth in a mouse
odel of glioma [118] whereas Lin28 has been reported to promote
ransformation in a mouse lung cancer cell line and its increased
xpression is strongly associated to advanced cancers [119].
.3. DNA replication, epigenetics and cancer
Adding another layer of complexity, certain proteins of the Poly-
omb group are known to be implicated in differentiation decisions
nd to be regulated by long non-coding RNAs (ncRNAs) some of
hich are emerging as possible tumor enhancing or repressive
enes [120]. For example, a long ncRNA from the HoxC locus termed
OTAIR (Hox transcript antisense intergenic RNA) is upregulated
n certain breast and colorectal cancers and seems to affect the
unction of the PRC2 Polycomb complex in a genome-wide scale
121]. Similarly, the SWI/SNF complex is believed to be important
n suppression of oncogenesis, as several inactivating mutations in
ts subunits have been recently identiﬁed in human cancers [122].
n this regard, Brg1, a SWI/SNF member and Geminin’s interac-
ing partner has been reported to function as a tumor suppressor
ene [123–125]. Similarly, CDC6 is known to interact with the Poly-
omb group protein Bmi1 [7], while c-Myc has been shown to
ranscriptionally regulate the expression of the same factor [126].
nterestingly, Bmi1 has also been immunoprecipitated with several
cRNAs [127]. Elaborating further on this issue, CTP synthase, a his-
one deacetylase-associated gene [128] shown to be deregulated in
 large number of cancers [129–133], is suspected of coding several
cRNAs [134].
. Conclusion
In conclusion, DNA replication, cancer, development and
luripotency appear to be interconnected. Pre-RC complex pro-
eins have distinct developmental roles and their deregulation can
ause genomic instability and cancer. Of note, it was recently shown
hat cancer cells have a higher number of active replication origins,
hen compared their non-cancer counterparts [135]. In line with
his, Di Paola and colleagues [136] reported a higher origin activity
n tumor cells, as compared to non-transformed ones, suggesting
reater origin activation. In addition, pluripotency-associated tran-
cription factors interact with DNA replication machinery while
heir overexpression has been strongly associated to cancer. In this
egard, a holistic model is proposed, whereby the choice of pro-
iferation versus differentiation (the “proliferation/differentiationevelopmental Biology 30 (2014) 174–180
seesaw”) shares a bidirectional relationship with the expression of
pre-RC components, the pattern of DNA replication origin ﬁring and
the epigenetic modiﬁcations (Fig. 2).
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